Evidence map›Paper›PMID 37256302›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2023

The role of EPID in vivo dosimetry in the risk management of stereotactic lung treatments.

Marco Esposito, Pietro Mancosu, Andrea Bruschi, Alessandro Ghirelli, Silvia Pini, Paolo Alpi, Raffaella Barca, Camilla Delli Paoli, Fiammetta Meacci, Barbara Grilli Leonulli and 4 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Marco EspositoS. C. Fisica Sanitaria, Firenze-Azienda Sanitaria USL Toscana Centro, Via dell'Antella 58, 50012, Bagno a Ripoli, Firenze, Italy. esposito@ictp.it.ORCID 0000-0002-9332-5351
Pietro MancosuMedical Physics Unit of Radiotherapy Dept., IRCCS Humanitas Research Hospital, Rozzano, Italy.
Andrea BruschiS. C. Fisica Sanitaria, Firenze-Azienda Sanitaria USL Toscana Centro, Via dell'Antella 58, 50012, Bagno a Ripoli, Firenze, Italy.
Alessandro GhirelliS. C. Fisica Sanitaria, Firenze-Azienda Sanitaria USL Toscana Centro, Via dell'Antella 58, 50012, Bagno a Ripoli, Firenze, Italy.
Silvia PiniS. C. Fisica Sanitaria, Firenze-Azienda Sanitaria USL Toscana Centro, Via dell'Antella 58, 50012, Bagno a Ripoli, Firenze, Italy.
Paolo AlpiS. C. Radioterapia, Firenze-Azienda Sanitaria USL Toscana Centro, Firenze, Italy.
Raffaella BarcaS. C. Radioterapia, Firenze-Azienda Sanitaria USL Toscana Centro, Firenze, Italy.
Camilla Delli PaoliS. C. Radioterapia, Firenze-Azienda Sanitaria USL Toscana Centro, Firenze, Italy.
Fiammetta MeacciS. C. Radioterapia, Firenze-Azienda Sanitaria USL Toscana Centro, Firenze, Italy.
Barbara Grilli LeonulliS. C. Radioterapia, Firenze-Azienda Sanitaria USL Toscana Centro, Firenze, Italy.
Simona FondelliS. C. Radioterapia, Firenze-Azienda Sanitaria USL Toscana Centro, Firenze, Italy.
Lisa PaolettiS. C. Radioterapia, Firenze-Azienda Sanitaria USL Toscana Centro, Firenze, Italy.
Silvia ScocciantiS. C. Radioterapia, Firenze-Azienda Sanitaria USL Toscana Centro, Firenze, Italy.
Serenella RussoS. C. Fisica Sanitaria, Firenze-Azienda Sanitaria USL Toscana Centro, Via dell'Antella 58, 50012, Bagno a Ripoli, Firenze, Italy.
Azienda Sanitaria di Firenze · ITIRCCS Humanitas Research Hospital · ITThe Abdus Salam International Centre for Theoretical Physics (ICTP) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveIn this work we report our experience with the use of in vivo dosimetry (IVD) in the risk management of stereotactic lung treatments.

methodsA commercial software based on the electronic portal imaging device (EPID) signal was used to reconstruct the actual planning target volume (PTV) dose of stereotactic lung treatments. The study was designed in two phases: i) in the observational phase, the IVD results of 41 consecutive patients were reviewed and out-of-tolerance cases were studied for root cause analysis; ii) in the active phase, the IVD results of 52 patients were analyzed and corrective actions were taken when needed. Moreover, proactive preventions were further introduced to reduce the risk of future failures. The error occurrence rate was analyzed to evaluate the effectiveness of proactive actions.

resultsA total of 330 fractions were analyzed. In the first phase, 13 errors were identified. In the active phase, 12 errors were detected, 5 of which needed corrective actions; in 4 patients the actions taken corrected the error. Several preventions and barriers were introduced to reduce the risk of future failures: the planning checklist was updated, the procedure for vacuum pillows was improved, and use of the respiratory compression belt was optimized. A decrease in the failure rate was observed, showing the effectiveness of procedural adjustment.

conclusionThe use of IVD allowed the quality of lung stereotactic body radiation therapy (SBRT) treatments to be improved. Patient-specific and procedural corrective actions were successfully taken as part of risk management, leading to an overall improvement in the dosimetric accuracy.

Indexed as

In Vivo DosimetryRadiotherapy, Intensity-ModulatedHumansLungRadiometryRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRisk ManagementContinuous Quality ImprovementOn line measurementsPatient Specific Quality AssurancePortal DosimetryQuality Assurance

Identifiers

PMID37256302
OpenAlexW4378783202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.